In the clinical trial, 67 percent of patients treated with Adcetris plus chemotherapy had neuropathy,
and 91 percent experienced low levels of certain blood cells.
Adcetris put my cancer into remission,
and I was able to get my second transplant, this time an allogeneic one, using my brother Lee as the stem cell donor.
At the precise moment I relapsed, just when I needed it most,
a drug called Adcetris, created by Seattle Genetics,
emerged, and it became available for a select group of people in my exact situation.